First-half FY2025 revenue rose 5.6% and net income nearly doubled, driven by machinery sales and asset gains. Full-year guidance was raised for revenue and profit, with all segments except pharmaceuticals showing growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.